ライフサイエンスコーパス: diagnostic use

1 ry approach but is not available for routine diagnostic use.

2 al human sweat for potential cystic fibrosis diagnostic use.

3 their ambiguous physical origin limits their diagnostic use.

4 eatment protocols towards true point-of-care diagnostic use.

5 aptation of new methods for routine clinical diagnostic use.

6 orter in the context of their therapeutic or diagnostic use.

7 ct level and may potentially allow for their diagnostic use.

8 ing this method into a clinically applicable diagnostic use.

9 gets available for potential therapeutic and diagnostic use.

10 of such reagents may have potential clinical diagnostic use.

11 the low sensitivity have limited its routine diagnostic use.

12 y titers determined in an ELISA approved for diagnostic use.

13 uman sweat and saliva and mouse serum enable diagnostic uses.

14 ve molecular recognition for therapeutic and diagnostic uses.

15 of the FilmArray respiratory panel (BioFire Diagnostics) using 129 respiratory specimens collected i

16 rating the feasibility of performing medical diagnostics using a logic gate design.

17 onds as an ultrasensitive label for in vitro diagnostics, using a microwave field to modulate emissio

18 We introduce the Antimicrobial Resistance Diagnostic Use Accelerator program, and the articles in

19 The AMR Diagnostics Use Accelerator Program was established to a

20 rk highlights the potential for health state diagnostics using all metabolomics features with data-dr

21 promising amyloid-beta radioligand both for diagnostic use and for evaluation of disease-modifying t

22 Specifically, we discuss the diagnostic use and potential of serologic tests based on

23 This makes routine diagnostic use and re-analysis of legacy data collection

24 These rapid tests are not recommended for diagnostic use, and further research is required to info

25 Many tests have both screening and diagnostic uses, and it is only the context in which the

26 d and Drug Administration (FDA) for in vitro diagnostic use, assays for the detection of SARS-CoV-2 n

27 Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specifici

28 Traditional technologies for molecular diagnostics using blood are limited to laboratory use be

29 issues have great potential for early cancer diagnostic use, but their clinical potential has not bee

30 l-free DNA and cell-free RNA relative to the diagnostic use case.

31 t the performance requirements necessary for diagnostic use cases, primarily due to the relatively lo

32 rapid field deployment of nucleic acid-based diagnostics using consumer-class quadcopter drones.

33 ave been conventionally assessed in clinical diagnostics using cytogenetic or microarray testing.

34 T. gondii infection to optimize the PCR for diagnostic use, define its sensitivity, and characterize

35 e well-calibrated CP estimates for precision diagnostics using DNA methylation data.

36 sibility of next-generation sequencing-based diagnostics using free circulating nucleic acids (cell-f

37 Molecular structure-based diagnostics using genus- and species-specific PCR, RFLP

38 Whereas single-center safety data for diagnostic use have been positive, multicenter data are

39 Improved diagnostics, using imaging, genetics, and biomarkers, ar

40 d develop them for research, therapeutic and diagnostic uses, improvements are needed in our ability

41 e number of new protein markers approved for diagnostic use in clinical laboratories.

42 rim width (BMO-MRW) assessment offers a new diagnostic use in glaucoma patients of the Glaucoma Modu

43 d tissue and may thus become a candidate for diagnostic use in humans.

44 S. Food and Drug Administration for in vitro diagnostic use in March 2007.

45 se staging in CHC continue to be refined for diagnostic use in other chronic liver disease such as NA

46 Molecular biomarkers are needed for diagnostic use in periodontal diseases.

47 ial decomposition algorithm hold promise for diagnostic use in the abdomen in lieu of true unenhanced

48 ernative techniques could provide adjunctive diagnostic use in the context of difficult-to-diagnose T

49 Standard diagnostics used in longitudinal antimalarial studies ar

50 sis techniques, we demonstrate that standard diagnostics used in the field are limited in their abili

51 date the impact of genetic variation on qPCR diagnostics using in vitro assays.

52 e pathobiology of cancer and other diseases, diagnostics using in vivo liquid biopsy, and drug delive

53 c high-temporal-resolution data for a target diagnostic using information from other diagnostics, wit

54 ve biomarker and limitations of conventional diagnostics using invasive specimens.

55 he immunological mechanisms underlying their diagnostic use is still incomplete.

56 Although these have yet to be validated for diagnostic use, it is likely that testing for myositis-s

57 p. target, and the recently cleared in vitro diagnostic use (IVD) Aptima BV assay includes a third ta

58 Once the (18)F tracers become available for diagnostic use, large-scale longitudinal studies will be

59 em (HOLMES) for amplification-free molecular diagnostics using massively paralleled and hierarchicall

60 vaginalis PCR performed better than routine diagnostics using microscopy for women and culture for m

61 We report a novel approach to intelligent diagnostics using microwave wide-band scattering informa

62 and overall mortality in patients with post-diagnostic use of cholera vaccine compared with matched

63 The radio-diagnostic use of CNN for sexual dimorphism showed posit

64 These data have important implications for diagnostic use of colon imaging tests.

65 Conclusions and Relevance: Diagnostic use of DSCMs shows promising correlation to f

66 Off-label diagnostic use of ferumoxytol, a superparamagnetic iron

67 bolic stress role in tumor survival, and the diagnostic use of imaging in prostate cancer were discus

68 s to investigate the association between pre-diagnostic use of metformin and WLM with all-cause and c

69 ticle summarizes our current concepts on the diagnostic use of MIBG in children.

70 a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in ca

71 Here we show that post-diagnostic use of PDE5 inhibitors is associated with a d

72 We aimed to explore whether post-diagnostic use of PDE5 inhibitors was associated with a

73 These results have implications for the diagnostic use of serum cystatin C as a marker of kidney

74 ndations based on the presented data include diagnostic use of sIgE to HMW allergens.

75 and "specificity" produces confusion in the diagnostic use of sophisticated laboratory test results.

76 There are limited data on the diagnostic use of the hepatic iron index in patients wit

77 atures in muscle, providing evidence for the diagnostic use of the technique, as well as insight into

78 -dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level.

79 Our main focus will be in describing the diagnostic uses of ultrasound to identify cardiac, pulmo

80 Finally, the broad range of diagnostic uses of US in these patients is presented, in

81 erence may provide Zher2 with advantages for diagnostic use or even for delivery of therapeutic agent

82 proof-of-concept applicability for real-time diagnostics using phase-corrected flexible ultrasound pr

83 Improved pediatric diagnostics using readily available biosources are urgen

84 assay (Simplexa Flu A/B & RSV Direct; Focus Diagnostics) using respiratory swabs (n = 197).

85 INTRODUCTION: Component-resolved diagnostics using specific IgE to 2 S albumins has shown

86 Component-resolved diagnostics using specific IgE to 2 S albumins has shown

87 ermined by a prototype test (now in clinical diagnostic use) that captures, enriches, and detects dis

88 Singleplex allergy diagnostics using the alpha-Gal analytes CTX and Bos d T

89 For differential diagnostic use, the primary utility of tau PET is to dif

90 ion (FDA)-authorized real-time PCR tests for diagnostic use, there are no FDA-authorized serological

91 Molecular diagnostics using tissue gene expression and blood-based

92 We determined the relationship across common diagnostics used to measure malaria prevalence - polymer

93 w-cost portable biosensors for point-of-care diagnostics using traditional optical, mass, or electroa

94 days were randomly assigned to: enhanced TB diagnostics using urine lipoarabinomannan (LAM) antigen

95 a novel development in both telemedicine and diagnostics using volatile biomarkers.

96 ressed in the literature, 207 for which only diagnostic use was addressed, 565 for which minimal or n

97 For potential diagnostic uses, we applied the system to detect dengue